Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners (PRACTISE)

Bayer

Status

Completed

Conditions

Venous Thromboembolism (VTE)

Treatments

Drug: Rivaroxaban (Xarelto, BAY59-7939)

Drug: Apixaban(Eliquis)

Drug: Pradaxa (Dabigatran etexilate)

Study type

Observational

Funder types

Industry

Identifiers

NCT03965741

20653

Details and patient eligibility

About

Patients with cancer are at a significantly increased risk of experiencing a venous thromboembolism (VTE). VTE is defined by a blood clot in the leg or lower extremity (deep vein thrombosis) or a blood clot in the lung (pulmonary embolism) and is a leading cause of condition of being diseased and death among cancer patients. The goal of the study is to gather information how often venous thromboembolism (VTE) occurs in prostate cancer patients in Sweden and how this condition is treated with blood thinners.

Enrollment

97,765 patients

Sex

Male

Volunteers

No Healthy Volunteers

Inclusion criteria

Initially all patients newly diagnosed with PCa between 2007-2016 with at least one year before the end of follow up date (31 December 2017) will be included. From this population, a sub-population of PCa patients with a first cancer-related VTE event will be selected.

Exclusion criteria